Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for weight loss after secondary bariatric surgery
NCT05285397Unknown
- Sponsor
- General Authority for Teaching Hospitals and Institutes
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of liraglutide in class III obesity (2 arms), sponsored by General Authority for Teaching Hospitals and Institutes. Primary endpoints: Percentage Total weight loss at 6 months and Percentage Excess body weight loss at 6 months. Status: unknown.
02
Drugs
03
Conditions
class III obesity
Beyond the preview
Go deeper on NCT05285397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285397.